Breaking News

Recipharm Audit Results in Licence Restriction

Five non-critical highly potent products from the Ashton-u-Lyne, UK site suspended due to potential cross contamination risk

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Following a routine audit, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has restricted the manufacturing license for five non-critical highly potent products supplied from the Recipharm facility located in Ashton-u-Lyne, UK. This was due to deficiencies in certain manufacturing procedures which represented a potential cross contamination risk. Recipharm’s facility in Ashton-u-Lyne, primarily manufactures non-potent solid dose products. Highly potent products are manufactu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters